<code id='BE643094D1'></code><style id='BE643094D1'></style>
    • <acronym id='BE643094D1'></acronym>
      <center id='BE643094D1'><center id='BE643094D1'><tfoot id='BE643094D1'></tfoot></center><abbr id='BE643094D1'><dir id='BE643094D1'><tfoot id='BE643094D1'></tfoot><noframes id='BE643094D1'>

    • <optgroup id='BE643094D1'><strike id='BE643094D1'><sup id='BE643094D1'></sup></strike><code id='BE643094D1'></code></optgroup>
        1. <b id='BE643094D1'><label id='BE643094D1'><select id='BE643094D1'><dt id='BE643094D1'><span id='BE643094D1'></span></dt></select></label></b><u id='BE643094D1'></u>
          <i id='BE643094D1'><strike id='BE643094D1'><tt id='BE643094D1'><pre id='BE643094D1'></pre></tt></strike></i>

          explore

          explore

          author:focus    Page View:387
          IQVIA signage. -- health tech coverage from STAT
          Adobe

          The health data giant IQVIA became a dominant force by gobbling up its rivals. Over decades, it feasted on upstarts with new datasets or novel technologies, growing into a juggernaut with no peer in the business of brokering Americans’ medical information.

          Now, government regulators say, IQVIA’s appetite for acquisition is getting out of control — and must be reined in.

          advertisement

          A Federal Trade Commission lawsuit seeking to block its acquisition of the digital advertising firm DeepIntent marks a crossroads for the company and the multi-billion dollar medical advertising economy it serves. The agency, which is seeking an injunction and temporary restraining order in federal court, argues that IQVIA’s data vault has become so large — and revealing — that it forms the substrate of an entire industry focused on showering doctors and patients with marketing messages.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Readout Newsletter: Bristol, Sangamo, Gilead, and more
          Readout Newsletter: Bristol, Sangamo, Gilead, and more

          EricRisberg/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsl

          read more
          Medical records are filled with copy
          Medical records are filled with copy

          AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

          read more

          What drug price negotiations mean for Medicare Part D

          AdobeAftertherecentannouncementofthefirst10drugsselectedforMedicarepricenegotiation,muchhasbeendiscu